Premium
P3‐038: Presence of cardiovascular disease is associated with slower cognitive decline in Alzheimer's disease in the absence of cerebrovascular pathology
Author(s) -
Chan Mark,
Pavlik Valory N.,
Chan Wenyaw,
Darby Eveleen,
Khaleeq Aisha,
Doody Rachelle S.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1531
Subject(s) - medicine , dementia , cognitive decline , comorbidity , diabetes mellitus , disease , clinical dementia rating , population , vascular dementia , cardiology , endocrinology , environmental health
significance for MCI relative to controls depended on the extent of multivariable adjustments for age, statin use, gender, and LDL (p1⁄4 0.18 unadjusted, p 1⁄4 0.04 fully adjusted). Female sex (p1⁄4 .048) and statin use (p< 0.001) were independently associated with lower Lp-PLA2 activity in the linear regression models adjusted for age and diagnosis (AD, MCI, control). In the overall study sample (n 1⁄4 236), Lp-PLA2 activity was moderately correlated with LDL (r 1⁄4 0.53, p < .001) and inversely correlated with HDL (r 1⁄4 -0.34, p < 0.001); the magnitude of correlations were similar within AD, MCI, and control diagnosis groups. Lp-PLA2 did not correlate with CSF biomarkers within diagnoses, apart from a marginally significant inverse association with CSF Ab42 in MCI (r 1⁄4 -0.25, p 1⁄4 0.04). AD subjects with APOE-e4 had higher Lp-PLA2 activity [207.9 (41.2)] than AD subjects lacking APOE-e4 [181.6 (26.0), p 1⁄4 0.003]. The effect was attenuated (p 1⁄4 0.09) after adjustment for LDL. Conclusions: APOE-e4, gender, statin use, LDL, and HDL are the main correlates of Lp-PLA2 activity in AD, MCI and cognitively healthy elderly.